|
INSM, ENMD, BGOI, COWI, SAPX, ATTD
Our Stocks to Watch tomorrow include Insmed Inc. (NASDAQ: INSM), EntreMed Inc. (NASDAQ: ENMD), Bonanza Oil & Gas Inc. (OTCBB: BGOI), CoroWare Inc. (OTC: COWI), Seven Arts Entertainment Inc. (NASDAQ: SAPX) and Attitude Drinks Inc. (OTCBB: ATTD).
INSMED INCORPORATED (NASDAQ: INSM)
"Up 31.84% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/INSM.php
Insmed Incorporated is a biopharmaceutical company focused on the development of innovative inhaled pharmaceuticals for the site-specific treatment of serious lung diseases, and has a proprietary protein platform aimed at niche markets with high unmet medical need. Insmed's primary focus is on the development of inhaled antibiotic therapy delivered via proprietary advanced pulmonary liposome technology in areas of high unmet need in lung diseases.
INSM News:
January 20 - Insmed Incorporated Provides Corporate Update
Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold previously placed on ARIKACE® (liposomal amikacin for inhalation) in patients with non-tuberculous mycobacteria (NTM) lung disease. Insmed continues to engage in discussions with FDA regarding the clinical hold placed on ARIKACE in Cystic Fibrosis (CF) patients with Pseudomonas lung infections.
The clinical holds placed on the ARIKACE programs in NTM and CF were based on an initial review by FDA of the results reported by Insmed of a long-term rat inhalation carcinogenicity study of ARIKACE.
FDA previously requested that Insmed conduct a phase 2 clinical trial of ARIKACE in adult patients with NTM to provide proof-of-concept efficacy and safety data before proceeding with a phase 3 clinical trial. As part of its on-going assessment of the appropriate path forward for the ARIKACE program, including the phase 2 trial of ARIKACE in NTM patients, the Company is continuing communication with FDA regarding the CF clinical hold.
Insmed also announced that it will move ahead with the 9-month dog inhalation toxicity study of ARIKACE as previously requested by FDA to determine if the findings of the rat inhalation carcinogenicity study are observed in a non-rodent model.
"We are pleased that FDA has lifted the clinical hold on the ARIKACE development program in NTM," said Timothy Whitten, President and CEO of Insmed. "Insmed continues to work closely with regulatory authorities regarding the development program for ARIKACE. We are initiating the work required to begin the 9-month dog study during the second quarter and are continuing our dialogue with FDA regarding the CF clinical program."
Insmed also announced that IPLEX® inventory has now been fully depleted. At present, about 10 patients remain on drug. Regarding potential future IPLEX initiatives, the Company is currently evaluating possible out-licensing opportunities for the drug.
ENTREMED INCORPORATED (NASDAQ: ENMD)
"Up 23.26% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/ENMD.php
EntreMed, Inc. is a clinical-stage pharmaceutical company committed to developing ENMD-2076, a selective angiogenic kinase inhibitor, for the treatment of cancer. ENMD-2076 is currently in a multi-center Phase 2 study in ovarian cancer and in several Phase 1 studies in solid tumors, multiple myeloma, and leukemia.
ENMD News:
November 14 - EntreMed Reports Third Quarter 2011 Financial Results
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, reported financial results for the three and nine-month periods ending September 30, 2011 .
EntreMed reported a net loss for the third quarter of 2011 of ( $1.3 million ), or ($0.13) per share. This compares with a net loss of ( $2.1 million ), or ($0.24) per share, for the same period last year. For the first nine months of 2011 the reported net loss was ($5.6 million ), or ($0.54) per share as compared to ( $9.2 million ), or ($1.09) per share for 2010.
As of September 30, 2011 , EntreMed had cash and cash equivalents of approximately $2.0 million .
Sara B. Capitelli , EntreMed's Vice President, Finance & Principal Accounting Officer, commented on the third quarter results, "Our financial results for the third quarter are in line with our expectations. Our research and development expenses for the third quarter decreased compared to the previous year as we completed enrollment of patients in the ENMD-2076 Phase 2 ovarian cancer study in 2011. We anticipate fourth quarter operating expenses to continue to decrease. In addition, we expect that the majority of our 2011 revenue will be from royalties on the sales of Thalomid®."
Michael M. Tarnow , EntreMed's Executive Chairman, further commented, "We are thankful to our shareholders for their support of EntreMed. We are moving forward with the planning process for the next clinical trial of ENMD-2076. The initiation of the next trial will necessitate additional resources, and we are continuing to pursue partnering and funding opportunities."
ABOUT ENMD-2076
ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action. ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers. ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases which have been shown to play important roles in the pathology of several cancers. ENMD-2076 has shown promising activity in Phase 1 clinical trials in solid tumor cancers, leukemia, and multiple myeloma. ENMD-2076 is currently in a Phase 2 trial for ovarian cancer, and preclinical and clinical activities are ongoing in assessing the compound's applicability for other forms of cancer.
BONANZA OIL & GAS INCORPORATED (OTCBB: BGOI)
"Up 33.33% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/BGOI.php
Based in Houston, TX, Bonanza Oil and Gas, Inc. holds assets ranging from current producing properties, wholly owned prospects, to developing working interests in Proven Undeveloped (PUDS) properties.
BGOI News:
January 13 - Investment Report On Bonanza Oil & Gas, Inc.
A Reuters Investment Profile has been released on Bonanza Oil & Gas, Inc. (OTCBB: BGOI). According to Reuters, “This report is essential reading for any serious investor, providing comprehensive financial information on a company's performance, position and cash flows over the past 3 years, including interim data.” To view the report, visit http://bit.ly/yVapQV.
COROWARE INCORPORATED (OTCBB: COWI)
"Up 100.00% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/COWI.php
Headquartered in Redmond, Washington, CoroWare is a solutions integrator with expertise in mobile robotics, personal telepresence, IT consulting and software development.
COWI News:
January 10 - Coroware Announces CoroBot Upgrades and Options
New Hardware Options and Software Upgrades Facilitate More Powerful Applications
CoroWare, Inc. (OTC: COWI) announced new software upgrades and hardware options for the CoroBot® Classic and CoroBot Explorer product lines. These new capabilities give researchers, educators and engineers the ability to rapidly develop more powerful autonomous unmanned ground vehicle (UGV) applications.
The software upgrades include full Robotic Operating System (ROS) compatibility and an improved teleoperation application. ROS is an open source framework for creating robotic applications, and is rapidly becoming an industry standard. All of CoroWare's mobile robots are designed to be fully ROS compatible. Out of the box, the CoroBot product line features a teleoperation application that allows users to remotely pilot the robot and view output from the cameras and sensors, whether over a private network or over the Internet.
"Our customers are looking for platforms that take advantage of open platforms such as ROS," said Andrew Zager , robotics product marketing engineer at CoroWare. "In addition to the applications developed by CoroWare, researchers and educators have access to a extensive catalog of open source robotic applications such as mapping, image recognition and navigation."
CoroWare is also offering new hardware options to enhance the abilities of the CoroBot product line. Customers can now add a Microsoft Kinect® to any CoroBot either pre-installed with ROS or upgraded to support ROS. Microsoft Kinect gives users infrared imaging and depth perception to create real-time three dimensional maps. In addition, the stock CoroBot camera has been upgraded to support 1080p full HD video quality.
With the needs of field researchers in mind, CoroWare is also offering customers the option of ordering Lithium Ferrous Phosphate (LiFePO4) batteries. These higher performance batteries offer higher power density and faster charge rates than typical unmanned vehicle batteries.
These new CoroBot product line upgrades and options are available today. The CoroBot product line includes a one year factory warranty at no additional charge. Customers have the option of purchasing extended warranty and premium support plans. Customers should contact a CoroWare account representative or authorized reseller for corporate and educational pricing details.
SEVEN ARTS ENTERTAINMENT INCORPORATED (NASDAQ: SAPX)
"Up 24.04% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/SAPX.php
Seven Arts Entertainment Inc. is the successor to Seven Arts Pictures Plc., which was founded in 2002 as an independent motion picture production and distribution company engaged in the development, acquisition, financing, production, and licensing of theatrical motion pictures for exhibition in domestic (i.e., the United States and Canada) and foreign theatrical markets, and for subsequent worldwide release in other forms of media, including home video and pay and free television.
SAPX News:
January 12 - Seven Arts Announces Start of Principal Photography on 'Schism'
Seven Arts Entertainment Inc. (NASDAQ: SAPX) ("Seven Arts") announced that principal photography on "Schism," the first film to be produced by Dark Arts, a division of Seven Arts' affiliate, Esplanade Pictures LLC ("Esplanade"), will start on Monday, January 16th in New Orleans.
"Schism," is written by Adam Gierasch and his partner Jace Anderson and will be directed by Gierasch. Seven Arts also announced that Callum Blue (Smallville), Vinnie Jones (Snatch) and Ashlynn Yennie (Human Centipede) will star in in the picture. Seven Arts has worked with Gierasch and Anderson previously on "Autopsy" and "Night of the Demons."
Esplanade will specialize in producing low-budget genre pictures in Louisiana, building on the strength and resources of its local Seven Arts' affiliate, Seven Arts Pictures Louisiana LLC.
Peter Hoffman, CEO of Seven Arts, commented, "We are pleased to announce our new collaboration with Adam Gierasch and Jace Anderson for 'Schism,' a frightening picture which will appeal both to Adam's core audience and to the wider audience for films with artistic and creative merit."
ATTITUDE DRINKS INCORPORATED (OTCBB: ATTD)
"Up 23.08% on Friday"
Detailed Quote: http://www.otcpicks.com/quotes/ATTD.php
Attitude Drinks Inc. is an innovative, beverage brand development company with a focus on functional milk, ready-to-drink beverages. Phase III® Recovery Drink is the company's first, functional milk drink exploiting recent scientific evidence of the benefits of milk and protein as an exercise recovery aid. The February 2010 launch of Phase III marks the first time a sports drink has been formulated from real milk.
ATTD News:
January 19 - Phase III® Recovery Drink to be Sold in Sam's Mart Stores; Distributed by Choice USA in NC, SC and Savannah Distributing in GA
Attitude Drinks (OTCBB: ATTD), an innovative brand beverage development company and owner of the Ready-to-Drink (RTD) real milk recovery drink, Phase III® Recovery, announced that Sam's Mart, Incorporated has authorized the sales of Phase III®. The recovery drink will be merchandised in all Sam's Mart stores in North Carolina, South Carolina and Georgia.
Jack Shea, Executive VP of Sales at Attitude, commented, "We are excited about the authorization of Phase III® in Sam's Mart. We expect to repeat the initial success of Phase III® in the Southeast as we have done in New England. The authorization in Sam's Mart is a big step in that direction."
"Our expansion into the North Carolina, South Carolina and Georgia region represents continued brand acceptance throughout the country, a gratifying and continuously inspiring accomplishment. Sam's Mart, Choice and Savannah Distributing are perfect examples of the relationships and quality partners that keep us excited as we begin the growth of the Phase III® brand," commented Roy Warren, CEO of Attitude.
Phase III® will be distributed to Sam's Mart by Choice USA Beverage, Inc. based out of Lowell, NC and Savannah Distributing Co., stationed in Savannah, GA.
ABOUT SAM'S MART INCORPORATED
Sam's Mart is headquartered in Matthews, N.C., and has annual sales in excess of $1 billion. The owner and employees of Sam's Mart opened the first store in June 1991, and the company has grown steadily over the ensuing years, largely through acquisitions. As of today, Sam's Mart operates a chain of 150 stores in Georgia, North Carolina and South Carolina.
|
